COVID-19：Shionogi，电晕药物的最终临床试验：S-217622
盐野木：
正在开发用于 COVID-19 治疗的口服药物。
9月28日，它宣布在日本开始了最后阶段的临床试验（clinical trial）。
电晕患者的药物：
行政主体是
轻度或无症状的新冠病毒感染者，
非常需要易于给药的药物。
口服药的功效：
Shionogi 开发的口服药物“会干扰病毒生长所必需的酶的作用”。
在感染的早期服用，以控制病情的严重程度，缓解发烧和咳嗽。
日本经济新闻
https://www.nikkei.com/article/DGXZQOUF282PZ0Y1A920C2000000/
Shionogi starts next phase of oral COVID drug test
Japanese pharmaceutical firm Shionogi
says it has begun a new phase in a clinical trial for an orally administered coronavirus treatment.
The Osaka-based company started first-phase tests in July this year.
The firm says it found no safety problems at that stage.
In the next round of tests that started on Monday,
the company is checking the drug’s efficacy and safety by administering it once a day for five days to COVID-19 patients with mild or no symptoms.
The tests
will target hospitalized patients and those who are recovering at accommodation facilities.
Shionogi
has not disclosed the scale and duration of the trial, but it aims to be ready by the end of this year to produce the drug for one million people.
Japan’s health ministry on Monday
approved sotrovimab, made by the British pharmaceutical giant GlaxoSmithKline,
for non-severe coronavirus cases, following an earlier approval of an antibody cocktail treatment.
Neither are administered orally.
NHK WORLD-JAPAN News